Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ASML Holding NV (ASML) vs Cassava Sciences Inc (FLNA) Price & Performance

ASML Holding NVTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

ASML Holding NV vs Cassava Sciences Inc — how do they compare? ASML Holding NV trades at $1,740.17 (market cap $688.66B), while Cassava Sciences Inc trades at $1.16 (market cap $57.49M). The key difference: ASML Holding NV is far larger — about 11978.8× Cassava Sciences Inc's market cap, and ASML Holding NV pays a 0.49% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

ASMLFLNA
Market Cap
$688.66B$57.49M
Sector
TechnologyHealth
52-Week High
$1.99K$4.64
52-Week Low
$689.63$1.16
Enterprise Value
$682.20B-$29.09M
Dividend Yield
0.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ASML Holding NV

ASML trades at $1,797.32, down 0.38% on the day, with technical indicators showing a bullish trend despite recent volatility. The company reported strong Q1 2026 earnings that beat expectations, with revenue reaching $32.67B in 2025 and net income margins of 29.71%. Analyst consensus remains strongly positive with 56.82% buy ratings and a $2,210 price target, though elevated valuation ratios (P/E 61.03) warrant caution.

ASML maintains a dominant position in advanced semiconductor equipment with robust profitability and growth prospects driven by AI infrastructure demand. Key risks include China export restrictions, competitive pressures, and high valuation multiples. The stock offers exposure to critical chip manufacturing technology but requires monitoring of earnings execution and geopolitical developments.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ASML Holding NV

Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.

Read more on ASML

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA